The complaint, filed by the Law Offices of Howard G. Smith, covers the period between February 10, 2025, and May 14, 2026. It asserts that Aardvark Therapeutics executives provided materially false information to the market, concealing critical adverse facts about the company's core operations. Specifically, the suit alleges that the firm overstated the safety profile of ARD-101, which in turn inflated expectations regarding the drug's clinical and regulatory prospects. Investors seeking to discuss their legal rights or participate in the action may reach the firm at (215) 638-4847 or via their website. Those who purchased shares during the specified timeframe are automatically considered class members, meaning they are not required to take immediate action to remain part of the suit.
Aardvark Therapeutics Faces Securities Fraud Class Action Lawsuit
Investors who incurred significant losses in Aardvark Therapeutics, Inc. (AARD) have until October 13, 2026, to file for lead plaintiff status in a pending class action lawsuit. The litigation centers on allegations that the company misled shareholders regarding the safety and commercial viability of its drug candidate, ARD-101.
Comments (0)
No comments yet. Be the first!